Tirzepatide and Semaglutide Discontinuation: Two-Thirds of Patients Maintain or Continue Weight Loss
Background
Obesity and overweight are global health challenges, often managed with GLP-1 receptor agonists (GLP-1RAs) like semaglutide and tirzepatide, which have demonstrated significant weight loss efficacy. A prevailing concern among patients and clinicians is the potential for rapid weight regain upon discontinuation of these medications, often necessitating lifelong treatment. However, real-world data on weight trajectories after stopping GLP-1RAs, particularly for newer dual agonists like tirzepatide, remains underexplored, leaving a critical gap in understanding long-term patient outcomes and informing post-treatment strategies.
Study Design
This retrospective cohort study analyzed electronic health records (EHR) from 4182 patients across a federated health network, tracking weight trajectories for 6 months following their last semaglutide or tirzepatide prescription. Data spanned from January 2021 to June 2025. A representative subset of 300 patients had their clinical notes curated using a large language model to identify documented treatment discontinuation around the time of the last prescription. The primary endpoint was weight change over the 6-month post-prescription period, comparing patients who maintained or lost weight against those who experienced regain.
Results
The study revealed that weight regain is not universal after GLP-1RA cessation. Approximately two-thirds (around 67%) of the 4182 patients demonstrated stable weight or continued weight loss during the 6 months following their last semaglutide or tirzepatide prescription. In the curated subset of 300 patients, 119 (40%) had documented treatment discontinuation. Within this specific group, a similar pattern emerged, with 72% of patients not demonstrating weight regain. Furthermore, exercise counseling was significantly more frequently documented among patients who achieved durable weight loss post-GLP-1RA discontinuation compared to those who experienced weight regain (26.2% vs. 14.7%; P = .04). These real-world observations challenge the assumption of inevitable weight rebound for all patients.
Key Findings
- Two-thirds of patients maintained stable weight or continued weight loss for 6 months after stopping semaglutide or tirzepatide.
- In a subset with documented discontinuation, 72% of patients did not experience weight regain.
- Exercise counseling was documented more often in patients with durable weight loss (26.2% vs. 14.7%; P = .04).
Why It Matters
This research offers a crucial shift in the narrative around GLP-1RA discontinuation, suggesting that weight regain is not an inevitable outcome for all patients. For individuals considering or undergoing GLP-1RA therapy, this provides a more nuanced expectation, potentially reducing anxiety about stopping treatment. The finding that exercise counseling correlates with durable weight loss highlights the critical role of lifestyle interventions in post-GLP-1RA management. Clinically, this suggests that integrating robust lifestyle support, particularly exercise guidance, could be a key component of "step-down" protocols after GLP-1RA cessation, moving towards more personalized and sustainable weight management strategies rather than assuming indefinite medication use.